[go: up one dir, main page]

BRPI0407680A - métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas - Google Patents

métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas

Info

Publication number
BRPI0407680A
BRPI0407680A BRPI0407680-0A BRPI0407680A BRPI0407680A BR PI0407680 A BRPI0407680 A BR PI0407680A BR PI0407680 A BRPI0407680 A BR PI0407680A BR PI0407680 A BRPI0407680 A BR PI0407680A
Authority
BR
Brazil
Prior art keywords
cancer
methods
cell metastasis
diagnosis
cancer cell
Prior art date
Application number
BRPI0407680-0A
Other languages
English (en)
Inventor
James P Quigley
John D Hooper
Jacqueline E Testa
Original Assignee
Novartis Ag
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag
Publication of BRPI0407680A publication Critical patent/BRPI0407680A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA DIAGNóSTICO DE CáNCER E DIMINUIçãO DE METáSTASE POR CéLULAS CANCEROSAS". A presente invenção refere-se a uma proteína que é uma proteína marcadora de tumor. Essa proteína pode ser usada para preparar anticorpos que se ligam à proteína marcadora de tumor. Esses anticorpos podem ser usados para reduzir ou eliminar metástase por células de câncer que produzem a proteína marcadora de tumor. Ainda, a invenção provê métodos que podem ser usados para diagnosticar cáncer e metástase por células de câncer.
BRPI0407680-0A 2003-02-19 2004-02-18 métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas BRPI0407680A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44882803P 2003-02-19 2003-02-19
PCT/EP2004/001556 WO2004074481A1 (en) 2003-02-19 2004-02-18 Glycorpotein antigen sima135 expressed in metastatic human tumor cells

Publications (1)

Publication Number Publication Date
BRPI0407680A true BRPI0407680A (pt) 2006-03-01

Family

ID=32908657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407680-0A BRPI0407680A (pt) 2003-02-19 2004-02-18 métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas

Country Status (13)

Country Link
US (4) US7589173B2 (pt)
EP (1) EP1597367B1 (pt)
JP (3) JP2007523836A (pt)
CN (1) CN100422328C (pt)
AT (1) ATE473279T1 (pt)
AU (1) AU2004213568A1 (pt)
BR (1) BRPI0407680A (pt)
CA (2) CA2516366A1 (pt)
DE (1) DE602004027992D1 (pt)
ES (1) ES2349128T3 (pt)
MX (1) MXPA05008794A (pt)
PT (1) PT1597367E (pt)
WO (1) WO2004074481A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10242146A1 (de) * 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
CA2516366A1 (en) * 2003-02-19 2004-09-02 Novartis Ag Glycorpotein antigen sima135 expressed in metastatic human tumor cells
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20080287309A1 (en) * 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
WO2007005502A2 (en) * 2005-06-30 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting cdcp1
JP2007112734A (ja) * 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
US8264715B2 (en) * 2006-04-25 2012-09-11 Ricoh Company, Ltd. Approach for implementing locked printing with remote unlock on printing devices
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
EP2447719B1 (en) * 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021087575A1 (en) * 2019-11-06 2021-05-14 Commonwealth Scientific And Industrial Research Organisation Binding proteins to cub domain-containing protein (cdcp1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
AU4441799A (en) 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
EP1301533A1 (de) * 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
CA2516366A1 (en) * 2003-02-19 2004-09-02 Novartis Ag Glycorpotein antigen sima135 expressed in metastatic human tumor cells
US20070266449A1 (en) * 2006-05-12 2007-11-15 Zivin Robert A Generation of animal models

Also Published As

Publication number Publication date
CA2787820A1 (en) 2004-09-02
JP5331071B2 (ja) 2013-10-30
WO2004074481A1 (en) 2004-09-02
US20120039891A1 (en) 2012-02-16
AU2004213568A1 (en) 2004-09-02
US20130142798A1 (en) 2013-06-06
US7589173B2 (en) 2009-09-15
US20100158917A1 (en) 2010-06-24
MXPA05008794A (es) 2006-03-10
CN1761750A (zh) 2006-04-19
US20040247601A1 (en) 2004-12-09
PT1597367E (pt) 2010-09-02
JP2011046712A (ja) 2011-03-10
JP2007523836A (ja) 2007-08-23
JP2013241416A (ja) 2013-12-05
ES2349128T3 (es) 2010-12-28
EP1597367B1 (en) 2010-07-07
ATE473279T1 (de) 2010-07-15
DE602004027992D1 (de) 2010-08-19
CA2516366A1 (en) 2004-09-02
CN100422328C (zh) 2008-10-01
EP1597367A1 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CU20120095A7 (es) Antagonistas de pcsk9
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
WO2007103770A8 (en) Compositions and methods for analyzing renal cancer
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
TW200639182A (en) Antibody variants and uses thereof
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EA200800094A1 (ru) Антитела cd19 и их использование
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
NZ602220A (en) Antibodies with ph dependent antigen binding
FI1897548T4 (fi) T-solujen säätely
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
WO2006076691A3 (en) Irta-2 antibodies and their uses
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
EP2210939A4 (en) Anti-bst2 antibody
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]